Menin-mll interaction inhibitor and preparation method therefor, and application

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
A Menin-MLL interaction inhibitor addresses the lack of effective treatments for diseases mediated by this interaction by offering a targeted therapeutic solution for tumors and diabetes.

HK40135697APending Publication Date: 2026-07-31BEYOND THERAPEUTICS CO LTD

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: HK62026123598
Authority / Receiving Office: HK · HK
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2023-09-27
Filing Date: 2026-05-19
Publication Date: 2026-07-31

Application Information

Patent Timeline

27 Sep 2023

Priority

19 May 2026

Application

HK62026123598

31 Jul 2026

Publication

HK40135697A

IPC: C07D487/04; C07D471/04; A61K31/537; A61K31/519; A61P35/00; A61P3/10; A61P37/02

Inventors: HU, QIYUE; HU, WEIMIN

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

Current treatments for diseases mediated by Menin-MLL interaction, such as tumors and diabetes, lack effective inhibitors targeting this interaction.

Method used

Development of a Menin-MLL interaction inhibitor compound.

Benefits of technology

The compound effectively targets and inhibits the Menin-MLL interaction, providing a potential therapeutic approach for diseases like tumors and diabetes.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

The invention discloses a Menin-MLL interaction inhibitor as well as a preparation method and application of the Menin-MLL interaction inhibitor. The compound is expected to be used for treating Menin-MLL interaction mediated diseases such as tumors and diabetes mellitus.

Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480060440.8 (22) Application Date 2024.09.23 (66) Domestic Priority Data 202311262366.1 2023.09.27 CN (85) PCT International Application Entering National Phase Date 2026.03.23 (86) PCT International Application Application Data PCT / CN2024 / 120409 2024.09.23 (87) PCT International Application Publication Data WO2025 / 067111 ZH 2025.04.03 (71) Applicant Suzhou Biyang Pharmaceutical Technology Co., Ltd. Address 215127 Unit E814, 5th Floor, Lecheng Plaza, Phase II, Biomedical Industrial Park, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Suzhou City, Jiangsu Province (72) Inventors: Hu Qiyue, Hu Weimin, Liu Suxing (74) Patent Agency: Beijing Linke Intellectual Property Agency (Special General Partnership) 11690 Patent Attorneys: Wang Lihong, Zhang Dan (51) Int.Cl. C07D 487 / 04 (2006.01) C07D 471 / 04 (2006.01) A61K 31 / 537 (2006.01) A61K 31 / 519 (2006.01) A61P 35 / 00 (2006.01) A61P 3 / 10 (2006.01) A61P 37 / 02 (2006.01) (54) Invention Title: A Menin-MLL Interaction Inhibitor, Its Preparation Method and Application (57) Abstract: This invention discloses a Menin-MLL interaction inhibitor, its preparation method and application. The compound is expected to be used in the treatment of diseases mediated by Menin-MLL interaction, such as tumors and diabetes. CN 121969626 A 2026.05.01 CN 1 21 96 96 26 A